313 related articles for article (PubMed ID: 18166783)
1. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Schmitt-Graeff AH; Teo SS; Olschewski M; Schaub F; Haxelmans S; Kirn A; Reinecke P; Germing U; Skoda RC
Haematologica; 2008 Jan; 93(1):34-40. PubMed ID: 18166783
[TBL] [Abstract][Full Text] [Related]
2. Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Remacha AF; Nomdedéu JF; Puget G; Estivill C; Sarda MP; Canals C; Aventin A
Haematologica; 2006 May; 91(5):719-20. PubMed ID: 16670082
[TBL] [Abstract][Full Text] [Related]
3. Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.
Tatic A; Vasilică M; Coliţă A; Vasilache D; Dobrea C; Jardan C; Găman AM; Crişan AM; Coliţă D; Coriu D
Rom J Morphol Embryol; 2013; 54(4):1177-82. PubMed ID: 24399021
[TBL] [Abstract][Full Text] [Related]
4. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.
Szpurka H; Tiu R; Murugesan G; Aboudola S; Hsi ED; Theil KS; Sekeres MA; Maciejewski JP
Blood; 2006 Oct; 108(7):2173-81. PubMed ID: 16741247
[TBL] [Abstract][Full Text] [Related]
5. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.
Broséus J; Alpermann T; Wulfert M; Florensa Brichs L; Jeromin S; Lippert E; Rozman M; Lifermann F; Grossmann V; Haferlach T; Germing U; Luño E; Girodon F; Schnittger S;
Leukemia; 2013 Sep; 27(9):1826-31. PubMed ID: 23594705
[TBL] [Abstract][Full Text] [Related]
6. [Clinical and biological features in refractory anemia with ringed sideroblasts with fluctuant platelet counts].
Ji O; Shen Q; Lin L; Zhang YC; Ji JM; Wu Y; Chen JY; Zhu GR; Kong XT; Xia W; Jiang PJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1036-41. PubMed ID: 20723324
[TBL] [Abstract][Full Text] [Related]
7. Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status.
Raya JM; Arenillas L; Domingo A; Bellosillo B; Gutiérrez G; Luño E; Piñán MA; Barbón M; Pérez-Sirvent ML; Muruzábal MJ; Yánez L; García L; Lemes A; Navarro JT; Elosegi A; Cortés MA; Villegas A; Durán MA; Ardanaz M; Florensa L;
Int J Hematol; 2008 Nov; 88(4):387-395. PubMed ID: 18820995
[TBL] [Abstract][Full Text] [Related]
8. MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count.
Steensma DP; Caudill JS; Pardanani A; McClure RF; Lasho TL; Tefferi A
Haematologica; 2006 Dec; 91(12 Suppl):ECR57. PubMed ID: 17194663
[TBL] [Abstract][Full Text] [Related]
9. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis.
Atallah E; Nussenzveig R; Yin CC; Bueso-Ramos C; Tam C; Manshouri T; Pierce S; Kantarjian H; Verstovsek S
Leukemia; 2008 Jun; 22(6):1295-8. PubMed ID: 18059483
[No Abstract] [Full Text] [Related]
10. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Renneville A; Quesnel B; Charpentier A; Terriou L; Crinquette A; Laï JL; Cossement C; Lionne-Huyghe P; Rose C; Bauters F; Preudhomme C
Leukemia; 2006 Nov; 20(11):2067-70. PubMed ID: 16990759
[No Abstract] [Full Text] [Related]
11. Refractory anemia with ring sideroblasts associated with marked thrombocytosis: a mixed group exhibiting a spectrum of morphologic findings.
Gurevich I; Luthra R; Konoplev SN; Yin CC; Medeiros LJ; Lin P
Am J Clin Pathol; 2011 Mar; 135(3):398-403. PubMed ID: 21350094
[TBL] [Abstract][Full Text] [Related]
12. Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category?
Wardrop D; Steensma DP
Br J Haematol; 2009 Mar; 144(6):809-17. PubMed ID: 19120370
[TBL] [Abstract][Full Text] [Related]
13. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features.
Wang SA; Hasserjian RP; Loew JM; Sechman EV; Jones D; Hao S; Liu Q; Zhao W; Mehdi M; Galili N; Woda B; Raza A
Leukemia; 2006 Sep; 20(9):1641-4. PubMed ID: 16871284
[No Abstract] [Full Text] [Related]
14. Refractory anemia with ring sideroblasts and RARS with thrombocytosis.
Patnaik MM; Tefferi A
Am J Hematol; 2015 Jun; 90(6):549-59. PubMed ID: 25899435
[TBL] [Abstract][Full Text] [Related]
15. The JAK2 V617F mutation is rare in RARS but common in RARS-T.
Ceesay MM; Lea NC; Ingram W; Westwood NB; Gäken J; Mohamedali A; Cervera J; Germing U; Gattermann N; Giagounidis A; Garcia-Casado Z; Sanz G; Mufti GJ
Leukemia; 2006 Nov; 20(11):2060-1. PubMed ID: 16932338
[No Abstract] [Full Text] [Related]
16. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Malcovati L; Della Porta MG; Pietra D; Boveri E; Pellagatti A; Gallì A; Travaglino E; Brisci A; Rumi E; Passamonti F; Invernizzi R; Cremonesi L; Boultwood J; Wainscoat JS; Hellström-Lindberg E; Cazzola M
Blood; 2009 Oct; 114(17):3538-45. PubMed ID: 19692701
[TBL] [Abstract][Full Text] [Related]
17. JAK2 V617F mutation is uncommon in patients with the 3q21q26 syndrome.
Lin P; Luthra R; Nussenzveig RH; Medeiros LJ
Hum Pathol; 2010 May; 41(5):758-62. PubMed ID: 20153505
[TBL] [Abstract][Full Text] [Related]
18. Development of refractory anemia with ring sideroblasts associated with thrombocytosis from pre-existing refractory anemia with ring sideroblasts through acquisition of Jak2 V617F mutation.
Lu CM; Zhou L; Wang E; Feng S; Sebastian S; Behler C
Leuk Lymphoma; 2011 Dec; 52(12):2405-7. PubMed ID: 21806348
[No Abstract] [Full Text] [Related]
19. [Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].
Zhang Y; Li L; Nie L; Yu Y; Yang YH; Zhang ZQ; Yang L; Xu SC; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):105-9. PubMed ID: 18681311
[TBL] [Abstract][Full Text] [Related]
20. UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation.
Szpurka H; Gondek LP; Mohan SR; Hsi ED; Theil KS; Maciejewski JP
Leukemia; 2009 Mar; 23(3):610-4. PubMed ID: 18818701
[No Abstract] [Full Text] [Related]
[Next] [New Search]